

- Nonsteroidal anti-inflammatory drugs (NSAIDs)
(*Cont.*):
for rhinovirus infections, 1203
for sickle cell arthropathy, 635
for SLE, 2130t, 2132
for spinal stenosis, 116
for subacute thyroiditis, 2299
for sunburn, 387
for tension-type headache, 2594
topical, 199, 2232, 2232t
for upper respiratory infections, 226
- Non-ST-segment elevation acute coronary syndrome (NSTE-ACS), **1593**
chest pain in, 96, 96t
clinical features of, 1594
diagnosis of, 1594–1595, 1594f, 1595f
ECG in, 297e-4f, 1457f, 1594
incidence of, 1593, 1594f
pathophysiology of, 1593–1594, 1594f
prognosis of, 1596t
risk stratification in, 1595, 1596f
treatment of, **1595**
ACE inhibitors, 1596
antithrombotic therapy, 747, 1596–1597, 1598t
beta blockers, 1596, 1597t
calcium channel blockers, 1596, 1597t
invasive vs. conservative strategy, 1597, 1598t
long-term management, 1597–1598
monitoring, 1595
morphine sulfate, 1597t
nitrates, 1595–1596, 1597t
PCI, 297e-3–4, 297e-3–4v, 1597. *See also* Percutaneous coronary interventions (PCI)
statins, 1596
- Nontropical sprue. *See* Celiac disease (gluten-induced enteropathy)
- Nontuberculous mycobacterial (NTM) infections, **1128**
bronchiectasis, 1128, 1694, 1696. *See also* Bronchiectasis
in children, 1130
diagnosis of, 205e-7–8, 1130–1131, 1131f
disseminated disease, 1129–1130
epidemiology of, 205e-7, 1128–1129
global considerations in, 1128–1129, 1132
lymphadenopathy, 1130
M. avium complex. *See* *Mycobacterium avium* complex (MAC) infections
M. marinum. *See* *Mycobacterium marinum* infections
pathobiology of, 1129, 1129f
prevention of, 1131
prognosis of, 1132
pulmonary disease, 1130
skin and soft tissue, 1130
treatment of, 205e-3–4, 205e-8, 1131–1132
- Noonan's syndrome, 436t, 1654
- Norepinephrine
action of, 444e-3t, 2637
in cardiac contraction, 265e-6
for cardiogenic shock, 1760–1761, 1761f
in cardiovascular regulation, 1613
clinical aspects of, 444e-3t
for neurogenic shock, 1750
for pulmonary edema, 1761f
reference values for, 2762t
for shock, 1750, 1751, 1757
structure of, 444e-3t
in vascular smooth-muscle cells, 265e-4
- Norethindrone, 2382
- Norfloxacin
action of, 931t, 932–933
for bacterial peritonitis prophylaxis, 288
for donovanosis, 198e-2
for infectious diarrhea, 857t
for peritonitis prophylaxis, 847
resistance to, 931t
- Norgestimate, 334
- Normal-pressure hydrocephalus, 175f, 2606–2607
- Normal saline. *See* Saline
- Normative economics, 15e-3
- Normeperidine, 92
- Normochromia, 81e-1
- Noroviruses, 1285, 1286f
- Norovirus (Norwalk virus) infections
clinical features of, 258, 266, 266t, 1286, 1286t
diagnosis of, 1286–1017
epidemiology of, 266, 855, 855t, 1285–1286
etiology of, 1285, 1286t
health care–associated, 917
immunity to, 1286
pathogenesis of, 1286
prevention of, 917, 1287
treatment of, 1287
- Norrie's disease, 222t
- North American Chest Pain Rule, 102f
- North Queensland tick typhus, 128t
- Nortriptyline
adverse effects of, 2710t
for chronic daily headache, 109
for depression, 2672, 2710t
for migraine prevention, 2594t
for nausea and vomiting, 260t
for neuropathic pain, 61, 93
for pain, 91t, 94, 2672
for smoking cessation therapy, 507, 2732
therapeutic monitoring of, 2765t
- Norwegian (crusted) scabies, 1263, 2744
- Nose
in granulomatosis with polyangiitis, 1443, 2183
in lepromatous leprosy, 1126
in relapsing polychondritis, 1443, 2203, 2203f
swab, specimen collection and transport, 150e-4t
- No-see-um midges, 2749
- Nosema* spp., 1408
- Nosocomial infections. *See* Health care–associated infections
- NO SPECS mnemonic, in Graves' disease, 2295
- NOTCH1* gene mutations, 1529
- NOTCH2* gene mutations, 135e-1
- NOTCH3* gene mutations, 2568
- NOTCH4* gene mutations, 2155
- NOTES (natural orifice transluminal endoscopic) surgery, 346e-1v, 1881, 1883, 1886f
- Nothnagel's syndrome, 208
- NPH insulin, 2411, 2411t
- NPHP2* gene mutations, 1855
- NPHS1/2* gene mutations, 1832
- NPM1* gene mutations, 680, 680t
- NRAMP1, 1106
- NRAS* gene mutations
cancers associated with, 101e-2t
in chronic myelomonocytic leukemia, 135e-6
in lung cancer, 507t, 509f
in melanoma, 496
- NREM sleep, 184–185, 185f
- NRG1* gene mutations, 465e-4
- NRL* gene mutations, 431t
- NRXN1* gene mutations, 465e-2
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs (NSAIDs)
- NSE. *See* Neuron-specific enolase (NSE)
- NSTE-ACS. *See* Non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
- N-terminal pro-BNP (NT-proBNP), 1505, 2762t
- NTM infections. *See* Nontuberculous mycobacterial (NTM) infections
- NTS (nucleus of the solitary tract), 213–214
- Nuclear factor- κ B (NF- κ B)
activation defects of, 420t
in asthma, 1674
essential modulator. *See* NEMO (NF- κ B essential modulator)
increased levels of, 102e-10
inhibition of, 102e-6, 102e-9f
nuclear translocation of, 145e-5, 145e-6f
receptor activator of. *See* RANK (receptor activator of NF κ B)
systems biology analysis of, 87e-2
- Nuclear membrane, inherited defects of, 1555t
- Nuclear-mitochondrial genomic cross-talk, 85e-7, 85e-7f
- Nuclear receptor(s), 400e-3, 400e-4, 400e-4f, 431t
- Nuclear receptor family, 400e-1
- Nuclear reprogramming, 454
- Nuclear transfer, 85e-9, 85e-10f
- Nuclear transplantation, 454
- Nuclear weapons, 263e-1, 263e-2
- Nucleic acid sequence–based amplification (NASBA), 1247, 1247t
- Nucleic acid tests
application of, 150e-8
nucleic acid amplification, 214e-9, 769t, 1247, 1247t
nucleic acid amplification strategies, 150e-7
probes for direct detection of pathogens, 150e-6–7
quantitative strategies, 150e-7–8
- Nucleocapsid, viral, 214e-1
- Nucleoside reverse transcriptase inhibitors. *See* Combination antiretroviral therapy (cART)
- Nucleosome, 427f, 431f
- 5'-Nucleotidase, in liver function evaluation, 1997
- Nucleotide repeat expansion disorders, 440, 440t
- Nucleotide reverse transcriptase inhibitors. *See* Combination antiretroviral therapy (cART)
- Nucleus of the solitary tract (NTS), 213–214, 213f
- Nucleus pulposus, herniated, 105
- Number needed to treat, 26
- Numbness, 158. *See also* Sensation
- Nummular eczema, 346
- Nummular headache, 2598
- Nummular skin lesions, 340t
- Nuocytes, 2116
- Nutrient(s)
definition of, 95e-1
digestion and absorption of, **1933**. *See also* *specific nutrients*
bile acids in, 1934–1935, 1934f, 1934t
gut microbiota and, 86e-6, 1875
in intestinal epithelia, 1933–1934
- Nutrient requirements, **95e-1**
in critically ill patient, 1734
factors altering, 95e-4–5
recommended intakes, **95e-1**
- Nutrient-sensing pathways, 94e-4–5
- Nutritional assessment, 95e-5, **461**
in acute care setting, 95e-5
in ambulatory setting, 95e-5–6
anthropometrics, 462
bedside, 462
of cancer patient, 474
in elderly, 81
global considerations in, 95e-6
in high-risk patient, 95e-6, 462t
laboratory studies in, 462, 464t
nutritional history in, 462
physical examination in, 462
for specialized nutritional support, 98e-1–2
- Nutritional monitoring, 95e-5
- Nutritional Screening Initiative, 276
- Nutritional short stature, 2258
- Nutritional supplements, 14e-3–4, 14e-4t, 95e-3
- Nutritional support/therapy
after bariatric surgery, 2398
for diabetes mellitus, 2408–2409, 2409t
for gastrointestinal disease, 1879
for hypertension, 1622t, 1623
for IBD, 2147
for irritable bowel syndrome, 1968–1969, 1968t
for metabolic syndrome, 2453
for MS, 2672
for myocardial infarction, 1606
for obesity, 2394–2396
for sepsis/septic shock, 1757
- Nutrition transition, 461
- Nyando virus, 1309t